Select a medication above to begin.
Dotarem
gadoterate meglumine
Black Box Warnings .
Risk with Inadvertent Intrathecal Administration
not approved for intrathecal use; intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, seizures
Nephrogenic Systemic Fibrosis
may result in fatal or debilitating fibrosis affecting skin, muscle, internal organs; avoid gadolinium-based contrast agents (GBCAs) in patients with impaired elimination of drugs, unless diagnostic info is essential and not available with non-contrasted MRI or other modalities; highest risk in patients with eGFR <30 or acute kidney injury; screen patients for acute kidney injury or other conditions that may reduce renal function; estimate GFR if patients at risk for chronically reduced renal function, including patients >60 yo and patients with HTN or diabetes; do not exceed recommended dose, allow sufficient time for drug elimination before re-administering in highest-risk patients; report any diagnosis of nephrogenic systemic fibrosis to Guerbet LLC at 1-877-729-6679 or FDA at 1-800-FDA-1088
Adult Dosing .
Dosage forms: INJ
magnetic resonance imaging, CNS
- [0.2 mL/kg/dose IV x1]
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment, on dialysis days consider administering right before dialysis; no supplement; PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
magnetic resonance imaging, CNS
- [0.2 mL/kg/dose IV x1]
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment, on dialysis days consider administering right before dialysis; no supplement; PD: not defined
hepatic dosing
- [not defined]